Oppenheimer lowered the firm’s price target on Apellis to $75 from $88 and Keeps an Outperform rating on the shares. While the firm is not ruling out an eventual approval for Syfovre, the firm sees a longer path towards educating the authorities on the evidence linking the drug’s benefit to functional benefit, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on APLS:
- Apellis price target lowered by $3 at Stifel, here’s why
- Apellis downgraded at Wells with pegcetacoplan EU approval ‘unlikely’
- Wells Fargo gets more bearish on Apellis, downgrades shares
- H.C. Wainwright remain buyers of Apellis despite clouded EU approval visibility
- Apellis Provides Update on Ongoing Regulatory Review of Pegcetacoplan for GA in the European Union